Back to search
FDAFDA · Food and drugs·Recall number D-1324-2014

BUPRENORPHINE HYDROCHLORIDE Sublingual Tablets, 2 mg, 30-count bottles, Rx only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-5378-56, UPC 3 0093-5378-56 5.

Published May 28, 2014 · Recall initiated: April 7, 2014

Summary

FDA records drug Class II recall D-1324-2014, published May 28, 2014 and initiated April 7, 2014. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 17,181 bottles; Lot: Lot #: 34013132A, 34013133A, 34013134A, 34013135A, 34013136A, Exp 11/14. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: High out of specification impurity test results were obtained during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide and Puerto Rico
Lot
Lot #: 34013132A, 34013133A, 34013134A, 34013135A, 34013136A, Exp 11/14
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was BUPRENORPHINE HYDROCHLORIDE Sublingual Tablets, 2 mg, 30-count bottles, Rx only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-5378-56, UPC 3 0093-5378-56 5. recalled?

Yes. FDA published recall D-1324-2014 on May 28, 2014. Reported hazard: Failed Impurities/Degradation Specifications: High out of specification impurity test results were obtained during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter